Keryx to host conference call with Dr. Lewis on Friday, May 6th at
8:00am EDT
NEW YORK, April 28, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that Edmund Lewis, MD, Co-Chairman of the Collaborative Study Group, will be presenting interim data from the Company's Phase II study of KRX-101 (oral sulodexide) for the treatment of diabetic nephropathy. Dr. Lewis will present the data during his presentation entitled "Treating Diabetic Nephropathy: From Serpents to Success" at the National Kidney Foundation's (NKF) 2005 Spring Clinical Meetings in Washington, D.C. Dr. Lewis' presentation is scheduled to begin at approximately 3:00pm EDT on Thursday, May 5, 2005, and will be held at the Marriott Wardman Park Hotel.
This presentation will not be webcast. A press release detailing the interim Phase II data discussed by Dr. Lewis will be issued by the Company and will be accessible via the Company's website at www.keryx.com.
On Friday, May 6, 2005, at 8:00am EDT, the Company will host a conference call, featuring Dr. Lewis, who will discuss the Keryx Phase II interim data presented during the NKF Meeting.
In order to participate in the conference call, please call 1-800-905-0392 (if calling from the U.S.) or 1-785-832-1508 (if calling from outside the U.S.). Conference ID: KERYX. The conference call also will be available for audio replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT THE COLLABORATIVE STUDY GROUP
The Collaborative Study Group (CSG), the largest standing renal clinical trials group in the world, is comprised of academic and tertiary care physician-researchers interested in collaborative clinical trials investigating new therapeutic approaches in the treatment of kidney disease. Since 1979, the CSG has conducted multiple large-scale clinical trials resulting in over 40 major publications in peer-reviewed journals. The CSG conducted pivotal trials of ACE Inhibition in Type 1 Diabetic Nephropathy and of Irbesartan in Type 2 Diabetic Nephropathy (I.D.N.T.), both of which led to FDA product registration for new indications and the recommendation of these agents as standard of care by the American Diabetes Association. The results of each of the CSG's last three major clinical trials were published in the New England Journal of Medicine. The IDNT multi-national trial in collaboration with Bristol-Myers Squibb and Sanofi-Synthelabo is the largest trial in renal disease to date, consisting of 1,715 patients from 210 investigative sites worldwide.
The CSG is conducting the Phase II clinical trial for KRX-101 and will be conducting the pending pivotal clinical program for KRX-101 including both the Phase III and Phase IV studies.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase II/III clinical program. Additionally, Keryx is developing clinical-stage oncology compounds including KRX-0401, a novel, first-in-class, oral AKT inhibitor in Phase II clinical trials. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.